Feed/Investors/Frazier Life Sciences

Frazier Life Sciences

The rounds this investor is named on, who it invests beside, and where it shows up.

Named on 2 rounds in the feed.

Rounds from 2025-03-03 to 2025-10-15

ROUNDS

led 1, joined 1

LED ROUNDS · USD

$187M

across 1 round

LATEST ROUND

Series C · $358.0M · 2025-10-15

CO-INVESTORS

named beside it

Rounds

[ 2 ]

The rounds this investor is named on, who it invests beside, and where it shows up.

Company	Round	Amount	Announced	Role
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers.	Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$358.0M	2025-10-15	[ PART ]
Callio Therapeutics Dual-payload antibody-drug conjugates (ADCs) for cancer treatment.	Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$187M	2025-03-03	[ LEAD ]